We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Abbott to Market Mad Cow Tests for Cattle

By Labmedica staff writers
Posted on 29 Mar 2001
Abbott Laboratories (Abbott Park, IL, USA) has entered into an agreement with Enfer Scientific Ltd. More...
(Tipperary, Ireland) for the marketing and distribution of two diagnostic tests developed by Enfer to detect bovine encephalopathy (BSE), or mad cow disease, in cattle. Abbott will market the tests under the Enfer name.

The tests detect the presence of the abnormal prion protein associated with BSE. One test is a four-hour enzyme-linked immunosorbent assay (ELISA), approved by the European Commission. The test's rapid turnaround time and high throughput capabilities make it well suited for testing for mad cow disease. The second test is a supplemental diagnostic test used to confirm positive results of the first test. Both tests are conducted on brain tissue and spinal cord samples from cattle.

"We believe we have two very effective tests that improve the speed and reliability of BSE testing,” said Louis Ronan, director of Enfer Scientific. "By helping to ensure that only BSE-free meat enters the human food chain, these tests are making an important contribution to public safety.”




Related Links:
Abbott Diagnostics

Gold Member
Fibrinolysis Assay
HemosIL Fibrinolysis Assay Panel
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Gold Member
Hematology Analyzer
Medonic M32B
8-Channel Pipette
SAPPHIRE 20–300 µL
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Whole-genome sequencing enables broader detection of DNA repair defects to guide PARP inhibitor cancer therapy (Photo courtesy of Illumina)

Whole-Genome Sequencing Approach Identifies Cancer Patients Benefitting From PARP-Inhibitor Treatment

Targeted cancer therapies such as PARP inhibitors can be highly effective, but only for patients whose tumors carry specific DNA repair defects. Identifying these patients accurately remains challenging,... Read more

Pathology

view channel
Image: AI models combined with DOCI can classify thyroid cancer subtypes (Photo courtesy of T. Vasse et al., doi 10.1117/1.BIOS.3.1.015001)

AI-Powered Label-Free Optical Imaging Accurately Identifies Thyroid Cancer During Surgery

Thyroid cancer is the most common endocrine cancer, and its rising detection rates have increased the number of patients undergoing surgery. During tumor removal, surgeons often face uncertainty in distinguishing... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.